A surprising, paradoxical relationship between a tumour suppressor molecule and an oncogene may be the key to explaining and working around how breast cancer tumour cells become desensitised to a common cancer drug, found researchers at the Perelman School of Medicine at the University of Pennsylvania.

The drug, lapatinib, activates the suppressor called FOXO, in HER2 breast cancer cells, but then FOXO becomes a turncoat molecule, working with an epigenetic regulator that controls gene expression.

This drug-triggered relationship induces the expression of the oncogene c-Myc, leading to reduced sensitivity to the cancer drug and eventually relapse.

They published their cover article today in Cancer Cell.

"We found that an epigenetic pathway is crucial for growth of HER2 cells and this epigenetic factor reduces sensitivity of the cancer cells to lapatinib, a HER2 inhibitor," said senior author Xianxin Hua, MD, PhD, a professor of Cancer Biology.

"We need to understand how the body initially responds to these drugs and why there is a relapse and devise a new tool to fix that."

Human epidermal growth factor receptor 2 (HER2) is upregulated in a subset of human breast cancers.

The HER2 pathway is mutated in many cancers, which drives tumours, but inhibitors of this pathway, such as lapatinib, have only limited success because cancer cells quickly adapt.

FOXO was normally thought of as the "good guy" molecule that controls cancerous cell growth, while c-Myc, the cancer-promoting molecule, the "bad guy."

However, FOXO becomes the agent that desensitises cells to cancer drugs, so this "good guy" molecule is converted to a "bad guy," during the treatment of the cancer cells with the anti-cancer drug.

"Now that we know about this triangle among FOXO, c-Myc, and the epigenetic pathway, we can stop c-Myc with an epigenetic inhibitor," Hua said.

"Multiple epigenetic regulators participate in the drug-desensitising pathway, so they could serve as new targets to improve therapy for this type of cancer."

The findings uncovered an adaptation pathway comprising the normally antagonising molecules FOXOs and c-Myc, which are regulated by epigenetic compounds.

Unravelling this complex interaction now gives researchers another point in the HER2 cancer pathway to hit.

Source: University Of Pennsylvania School Of Medicine